SCHEMBL3756488

SCHEMBL3756488

O=C(Cc1ccccc1-c1[c]nccc1)N1CCNCC1

nearest known ligand 0.39

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
FNTA P49354 1/20 0.39
FNTB P49356 1/20 0.39
RBP4 P02753 1/20 0.38
KMT2A Q03164 4/20 0.37
KDM4E B2RXH2 3/20 0.37
ALDH1A1 P00352 3/20 0.37
SIGMAR1 Q99720 1/20 0.37
SCN7A Q01118 1/20 0.35
KCNH2 Q12809 1/20 0.35
TPSAB1 Q15661 1/20 0.34
TPSD1 Q9BZJ3 1/20 0.34
TPSG1 Q9NRR2 1/20 0.34
MKNK1 Q9BUB5 1/20 0.34
MKNK2 Q9HBH9 1/20 0.34
MAPK1 P28482 1/20 0.34
MEN1 O00255 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3758804 0.89 RBP4 (0.40) FNTAFNTBRBP4KMT2AKDM4E
SCHEMBL3756653 0.89 RBP4 (0.40) FNTAFNTBRBP4KMT2AKDM4E
SCHEMBL3765084 0.88 HPGD (0.41) FNTAFNTBRBP4KMT2AKDM4E
SCHEMBL3757735 0.80 RXFP1 (0.52) KMT2AALDH1A1SIGMAR1MKNK1MKNK2
SCHEMBL3769531 0.79 LMNA (0.48) SIGMAR1
SCHEMBL3757381 0.76 POLB (0.48) KMT2AKDM4EALDH1A1SIGMAR1MAPK1
SCHEMBL3759011 0.75 CXCR4 (0.48) KMT2ASIGMAR1MEN1
SCHEMBL3765034 0.74 HTR2C (0.35) KMT2AALDH1A1SIGMAR1MKNK1MKNK2
SCHEMBL3758914 0.74 GAA (0.37) KMT2AALDH1A1MEN1
SCHEMBL3760092 0.72 KDM4E (0.38) KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2029570-B1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA SA (BE) 2014-10-15 EP disclosed
US-8324204-B2 Fused thiophene derivatives as kinase inhibitors UCB PHARMA SA (BE) 2012-12-04 US disclosed
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors UCB PHARMA S.A. (BE) 2010-12-02 US disclosed
WO-2009122148-A1 FUSED THIOPHENE AND THIAZOLE DERIVATIVES AS PI3K KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-10-08 WO disclosed
WO-2009071890-A1 TRICYCLIC KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 WO disclosed
WO-2009071895-A1 FUSED THIAZOLE AND THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 WO disclosed
EP-2029570-A1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB Pharma S.A. (BE) 2009-03-04 EP disclosed
WO-2007141504-A1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2007-12-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors PIKFYVE, PI4KA, PIK3CA FNTA 3690/4885FNTB 3791/4885RBP4 2961/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.